Clinical and Molecular Outcomes of Dabrafenib/Trametinib-Based Combination Therapy in Acquired BRAF V600E-Mutant NSCLC Following Tyrosine Kinase Inhibitor Resistance: A Preliminary Single-Center Retrospective Study
Acquired BRAF V600E is an uncommon resistance mechanism after tyrosine kinase inhibitor (TKI) therapy in oncogene-driven non-small cell lung cancer (NSCLC), and the clinical value of dabrafenib/trametinib-based combination therapy remains unclear. This preliminary single-center retrospective study aimed to describe...